GlaxoSmithKline And Vir Biotechnology Kick Off ACTIV-3 Covid Trial
GlaxoSmithKline And Vir Biotechnology Kick Off ACTIV-3 Covid Trial Thu, 17th Dec 2020 21:45 (Alliance News) - GlaxoSmithKline PLC and Vir Biotechnology Inc said Thursday they have started the US National Institutes of Health sponsored ACTIV-3 trial for evaluating VIR-7831 in hospitalised adults with Covid-19. The pair said that the first patient has been dosed in a new sub-trial of the NIH's Accelerating Covid-19 Therapeutic Interventions & Vaccines Program Phase 3 clinical trial. This trial is designed to evaluate the safety and efficacy of VIR-7831 for the treatment of hospitalised adults w...
Source: lse.co.uk